Squarepoint Ops LLC Purchases 286,160 Shares of Heron Therapeutics, Inc. (NASDAQ:HRTX)

Squarepoint Ops LLC raised its position in Heron Therapeutics, Inc. (NASDAQ:HRTX - Free Report) by 369.0% during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor owned 363,700 shares of the biotechnology company's stock after acquiring an additional 286,160 shares during the period. Squarepoint Ops LLC owned about 0.24% of Heron Therapeutics worth $1,273,000 as of its most recent filing with the SEC.

Several other institutional investors have also recently bought and sold shares of HRTX. nVerses Capital LLC bought a new stake in shares of Heron Therapeutics during the 2nd quarter worth approximately $27,000. Headlands Technologies LLC acquired a new position in shares of Heron Therapeutics during the 1st quarter worth approximately $30,000. Susquehanna Fundamental Investments LLC acquired a new position in shares of Heron Therapeutics during the 1st quarter worth approximately $32,000. HB Wealth Management LLC acquired a new position in shares of Heron Therapeutics during the 2nd quarter worth approximately $35,000. Finally, Sei Investments Co. acquired a new position in shares of Heron Therapeutics during the 2nd quarter worth approximately $44,000. Institutional investors own 80.01% of the company's stock.

Heron Therapeutics Stock Up 2.4 %

Heron Therapeutics stock traded up $0.05 during trading hours on Friday, hitting $2.12. The stock had a trading volume of 1,333,770 shares, compared to its average volume of 2,521,240. The stock has a market cap of $319.38 million, a price-to-earnings ratio of -3.48 and a beta of 1.80. Heron Therapeutics, Inc. has a one year low of $0.50 and a one year high of $3.93. The business's 50 day simple moving average is $2.06 and its 200-day simple moving average is $2.72.

Heron Therapeutics (NASDAQ:HRTX - Get Free Report) last issued its quarterly earnings data on Tuesday, August 6th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.04) by ($0.02). The firm had revenue of $36.02 million during the quarter, compared to the consensus estimate of $35.35 million. During the same period last year, the business earned ($0.35) EPS. Research analysts anticipate that Heron Therapeutics, Inc. will post -0.1 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have commented on HRTX shares. Rodman & Renshaw started coverage on Heron Therapeutics in a report on Thursday, June 13th. They issued a "buy" rating and a $7.00 price objective on the stock. Needham & Company LLC reaffirmed a "buy" rating and issued a $5.00 price objective on shares of Heron Therapeutics in a report on Wednesday, September 25th.

Heron Therapeutics Profile

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.